Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Julia Miriam Weiss"'
Autor:
Christian Molnar, Sheila Bohler, Jovana Rajak, Julia Miriam Weiss, Irene Gonzalez-Mendez, Geoffroy Andrieux, Eva-Maria Demmerath, Madeleine Wahl, Lena Wendeburg, Gudrun Göhring, Brigitte Strahm, Doris Steinemann, Martina Rudelius, Melanie Börries, Leticia Quintanilla-Martinez, Charlotte M. Niemeyer, Verena Labi, Miriam Erlacher
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100069- (2023)
Externí odkaz:
https://doaj.org/article/eb53d0919a71441d88fd83a5986a697d
Autor:
Charlotte Wantzen, Baris Yigit, Yuan Suo, Roland Meisel, Shu Zang, Julia Miriam Weiss, Juncal Fernandez-Orth, Miriam Erlacher
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100087- (2023)
Externí odkaz:
https://doaj.org/article/fe7fb250e7e9429eba63207d10553d1b
Autor:
Michal Izrael, Kfir Molakandov, Ariel Revel, Shalom Guy Slutsky, Tehila Sonnenfeld, Julia Miriam Weiss, Michel Revel
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Background: An acute respiratory distress syndrome (ARDS) is caused by the increased amounts of pro-inflammatory cytokines and neutrophil-mediated tissue injury. To date, there is no effective treatment for the ARDS available, while the need for one
Externí odkaz:
https://doaj.org/article/4e669f64b52142248ccc4e18b56f57ea
Autor:
Sheila Bohler, Sehar Afreen, Juncal Fernandez-Orth, Eva-Maria Demmerath, Christian Molnar, Ying Wu, Julia Miriam Weiss, Venugopal Rao Mittapalli, Lukas Konstantinidis, Hagen Schmal, Mirjam Kunze, Miriam Erlacher
Publikováno v:
Haematologica, Vol 106, Iss 12 (2020)
BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in
Externí odkaz:
https://doaj.org/article/56e18fa348d74b2baa4702881af13610
Autor:
Eva-Maria Demmerath, Christian Molnar, Venugopal Rao Mittapalli, Sheila Bohler, Miriam Erlacher, Lukas Konstantinidis, Ying Wu, Hagen Schmal, Mirjam Kunze, Juncal Fernandez-Orth, Sehar Afreen, Julia Miriam Weiss
Publikováno v:
Haematologica
BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already approved by the Food and Drug Administration, BCL-XL and MCL-1 inhibitors are currently in
Autor:
Fabienne Regnier, Alain Trautmann, Grégoire Altan-Bonnet, Lene Vimeux, Marion V. Guérin, Julia Miriam Weiss, Vincent Feuillet, Nadège Bercovici, Emmanuel Donnadieu
Publikováno v:
Live Talks.
Background Activation of the STimulator of INterferon Genes (STING) by DMXAA (5,6-dimethylxanthenone-4-acetic acid) can induce a strong production of IFNα/β and the rejection of transplanted primary tumors. However, the efficacy of such therapeutic
Autor:
Alexandra Müller, Sehar Afreen, Julia Miriam Weiss, Eva-Maria Demmerath, Kristina Schachtrup, Jonas S. Jutzi, Sheila Bohler, Mirjam Kunze, Miriam Erlacher
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 1, Pp 1-15 (2020)
Cell Death and Disease, Vol 11, Iss 1, Pp 1-15 (2020)
The anti-apoptotic BCL-2 proteins (BCL-2, BCL-XL, MCL-1, A1, BCL-W) counteract apoptotic signals emerging during development and under stress conditions, and are thus essential for the survival of every cell. While the “BCL-2 addiction” of differ
Autor:
Emmanuel Donnadieu, Thomas Guilbert, Vincent Feuillet, Fabienne Regnier, Maxime Thoreau, Veronica Finisguerra, Alain Trautmann, Lene Vimeux, Nadège Bercovici, Julia Miriam Weiss, Marion V. Guerin, Gilles Renault
Publikováno v:
Nature Communications
Nature Communications, 2019, 10 (1), ⟨10.1038/s41467-019-11998-w⟩
Nature Communications, Nature Publishing Group, 2019, 10 (1), ⟨10.1038/s41467-019-11998-w⟩
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Nature Communications, 2019, 10 (1), ⟨10.1038/s41467-019-11998-w⟩
Nature Communications, Nature Publishing Group, 2019, 10 (1), ⟨10.1038/s41467-019-11998-w⟩
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Type I interferons (IFN) are being rediscovered as potent anti-tumoral agents. Activation of the STimulator of INterferon Genes (STING) by DMXAA (5,6-dimethylxanthenone-4-acetic acid) can induce strong production of IFNα/β and rejection of transpla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e17412bd5ea94db5b6ff7a7d04c5eb2
https://hal.archives-ouvertes.fr/hal-02404270
https://hal.archives-ouvertes.fr/hal-02404270
Autor:
Y Wu, Miriam Erlacher, Venugopal Rao Mittapalli, Sheila Bohler, Christian Molnar, Julia Miriam Weiss, N Koleci
Publikováno v:
Klinische Pädiatrie.
Autor:
Melanie Börries, Leticia Quintanilla-Martinez, I Gonzalez, Julia Miriam Weiss, I Schmitt, VM Mittapalli, Geoffroy Andrieux, Charlotte M. Niemeyer, Christian Molnar, Miriam Erlacher
Publikováno v:
Klinische Pädiatrie.